The effect of interferon-α2b on PD-1/PD-L1 signaling pathway of HEL cells

doi:10.3969/j.issn.1674-490X.2022.03.001

Abstract

Abstract: Objective To study the effects of interferon-α2b(IFN-α2b)on proliferation and apoptosis and the influence with programmed death-1(PD-1)and programmed death ligand-1(PD-L1)of JAK2 V617F positive human erythroleukemia HEL cells. Methods Different concentrations of IFN-α2b were applied to human erythroleukemia HEL cell lines. CCK-8 was used to detect cell viability and caspase-3/7 activity was detected by caspase-3/7 activity assay kit. The expression levels of JAK2, PD-1 and PD-L1 mRNA were detected by fluorescence quantitative PCR. Flow cytometry was used to detect the effects of different concentrations of interferon-α2b on the expression of PD-1 and PD-L1 protein in HEL. Results Different concentrations of IFN-α2b could inhibit HEL cell proliferation in time and dose-dependent manner. IFN-α2b could increase caspase-3/7 activity of HEL cells in a dose and time-dependent manner; IFN-α2b could reduce JAK2 V617F mutation in a dose-dependent manner,inhibit the expression of PD-1 mRNA and protein, and slightly increase the expression of PD-L1.Conclusion IFN -α2b may inhibit HEL proliferation and participate in the regulation of PD-1/PD-L1 expression.

Key words: interferon alpha, JAK2 V617F mutation, HEL cells, programmed death-1, programmed death ligand-1

CLC Number:

R733.3

QI Lin,CHENG Zhiyong,ZHANG Lijun,WANG Meng,WANG Baoyan. The effect of interferon-α2b on PD-1/PD-L1 signaling pathway of HEL cells[J]. Journal of Hebei Medical College for Continuing Education, 2022, 39(3): 1-8.

References

[1] 沈庆慧,郭玉洁,薛春娥,等. BCR-ABL阴性骨髓增殖性肿瘤208例临床分析[J].中国实验血液学杂志, 2019, 27(1): 159-164.
[2] 崔文静,朱华锋,董莹,等.132例BCR-ABL融合基因阴性骨髓增殖性肿瘤患者JAK2、CALR及MPL基因突变的临床分析[J].现代肿瘤医学, 2018, 26(24): 4011-4014. DOI: 10.3969/j.issn.1672-4992.2018.24.031.
[3] DE LEÓN C P, LORITE P, LÓPEZ-CASADO M Á, et al. Significance of PD1 alternative splicing in celiac disease as a novel source for diagnostic and therapeutic target[J]. Front Immunol, 2021, 12: 678400. DOI:10.3389/fimmu.2021.678400.
[4] DIETERICH L C, IKENBERG K, CETINTAS T, et al. Tumor-associated lymphatic vessels upregulate PDL1 to inhibit T-cell activation[J]. Front Immunol, 2017, 8: 66. DOI: 10.3389/fimmu.2017.00066.
[5] KOWANETZ M, ZOU W, GETTINGER S N, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab(anti-PD-L1)[J]. Proc Natl Acad Sci USA, 2018, 115(43): E10119-E10126. DOI: 10.1073/pnas.1802166115.
[6] LIU B, ARAKAWA Y, YOKOGAWA R, et al. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes[J]. PLoS One, 2018, 13(4): e0194594. DOI: 10.1371/journal.pone.0194594.
[7] PIANKO M J, LIU Y Z, BAGCHI S, et al. Immune checkpoint blockade for hematologic malignancies: a review[J]. Stem Cell Investig, 2017, 4: 32. DOI: 10.21037/sci.2017.03.04.
[8] WANG X, TENG F F, KONG L, et al. PD-L1 expression in human cancers and its association with clinical outcomes[J]. Onco Targets Ther, 2016, 9: 5023-5039. DOI: 10.2147/OTT.S105862.
[9] CHIOU V L, BUROTTO M. Pseudoprogression and immune-related response in solid tumors[J]. J Clin Oncol, 2015, 33(31): 3541-3543. DOI: 10.1200/JCO.2015.61.6870.
[10] STEIN B L, TIU R V. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms[J]. J Interferon Cytokine Res, 2013, 33(4): 145-153. DOI: 10.1089/jir.2012.0120.
[11] KOLLMANN S, GRUNDSCHOBER E, MAURER B, et al. Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia[J]. Leukemia, 2019, 33(7): 1583-1597. DOI: 10.1038/s41375-018-0369-5.
[12] 韩瑞玲,李艳,汪明,等.BCR/ABL阴性的骨髓增殖性疾病患者JAK2V617F点突变的研究[J].现代检验医学杂志, 2014,29(2): 29-31.
[13] 刘贵敏,张丽军,付建珠,等.Ruxolitinib对JAK2V617F阳性骨髓增殖性肿瘤细胞基质金属蛋白酶调控的研究[J].中华血液学杂志, 2017, 38(2): 140-145.
[14] 徐倩,赵亚玲,付建珠,等.AG490对HEL细胞VEGF和HIF-1α表达的影响[J].中国病理生理杂志, 2015, 31(12): 2158-2163. DOI: 10.3969/j.issn.1000-4718.2015.12.008.
[15] 付建珠,徐倩,赵亚玲,等.干扰素抑制JAK2V617F阳性骨髓增殖性肿瘤血管新生的机制[J].中华医学杂志, 2015, 95(46): 3727-3732. DOI: 10.3760/cma.j.issn.0376-2491.2015.46.002.
[16] 赵亚玲,张丽军,付建珠,等.IFN-α2b对JAK2V617F突变的骨髓增殖性肿瘤COX-2表达及血管新生的影响[J].四川大学学报(医学版), 2016, 47(4): 473-478. DOI: 10.13464/j.scuxbyxb.2016.04.005.
[17] CRISÀ E, CERRANO M, BEGGIATO E, et al. Can pegylated interferon improve the outcome of polycythemia vera patients? [J]. J Hematol Oncol, 2017, 10(1): 15. DOI: 10.1186/s13045-017-0395-1.
[18] 谢旭磊,杨圣俊,郝洪岭,等. SOCS1、SHP1在JAK2V617F突变阳性骨髓增殖性肿瘤中的表达及鲁索替尼的调控作用[J].第二军医大学学报, 2018, 39(1): 74-80. DOI: 10.16781/j.0258-879x.2018.01.0074.
[19] LEI Q Y, WANG D, SUN K, et al. Resistance mechanisms of anti-PD1/PDL1 therapy in solid tumors[J]. Front Cell Dev Biol, 2020, 8: 672. DOI: 10.3389/fcell.2020.00672.
[20] 徐一清,刘勇.PD-1/PD-L1抑制剂免疫相关不良反应的研究进展[J].实用肿瘤杂志, 2020, 35(6): 491-494. DOI: 10.13267/j.cnki.syzlzz.2020.06.003.
[21] MARUYAMA D, HATAKE K, KINOSHITA T, et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma[J]. Cancer Sci, 2017, 108(5): 1007-1012. DOI: 10.1111/cas.13230.
[22] ZHANG L, GAJEWSKI T F, KLINE J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model[J]. Blood, 2009, 114(8): 1545-1552. DOI: 10.1182/blood-2009-03-206672.
[23] YANG K, XU J, LIU Q H, et al. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia[J]. Pathol Res Pract, 2019, 215(2): 265-271. DOI: 10.1016/j.prp.2018.10.021.
[24] KRÖNIG H, KREMMLER L, HALLER B, et al. Interferon-induced programmed death-ligand 1(PD-L1/B7-H1)expression increases on human acute myeloid leukemia blast cells during treatment[J]. Eur J Haematol, 2014, 92(3): 195-203. DOI: 10.1111/ejh.12228.
[25] 董荣乔,周东方,韩冉,等.干扰素α对慢性丙型肝炎患者外周血T淋巴细胞表面程序性死亡受体-1表达的影响[J].中华肝脏病杂志, 2013,21(12): 899-902.
[26] 成志勇,张丽军,付建珠,等.PD-1/PD-L1及Treg细胞在JAK2 V617F阳性骨髓增殖性肿瘤中的表达及意义[J].中山大学学报(医学版), 2019, 40(1): 98-103. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2019.0013.